TR201900515T4 - Bir adrenal hormonunu modifiye eden ajanın kullanımı. - Google Patents

Bir adrenal hormonunu modifiye eden ajanın kullanımı. Download PDF

Info

Publication number
TR201900515T4
TR201900515T4 TR2019/00515T TR201900515T TR201900515T4 TR 201900515 T4 TR201900515 T4 TR 201900515T4 TR 2019/00515 T TR2019/00515 T TR 2019/00515T TR 201900515 T TR201900515 T TR 201900515T TR 201900515 T4 TR201900515 T4 TR 201900515T4
Authority
TR
Turkey
Prior art keywords
hydrogen
aryl
modifying agent
alkyl
subject
Prior art date
Application number
TR2019/00515T
Other languages
English (en)
Inventor
Hu Qi-Ying
Ksander Gary
Meredith Erik
G Monovich Lauren
Papillon Julien
Schumacher Christoph
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900515(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR201900515T4 publication Critical patent/TR201900515T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Mevcut buluş, bir öznedeki artan stres hormonu seviyeleri ve/veya azalan androjen hormonu seviyeleri ile karakterize edilen bir hastalık veya bozukluğun tedavi edilmesine yönelik bir yöntem ile ilgilidir, yöntem formül (I) ile temsil edilen bir bileşiğin veya farmasötik olarak kabul edilebilir bir tuzunun terapötik olarak etkili bir miktarının özneye uygulanmasını içerir: burada n, 1 veya 3'tür; R, hidrojen veya --C(O)N(Ra)(Rb)'dir burada Ra ve Rb bağımsız olarak --(C1-C4) alkil, veya --(C1-C4) alkil-(C5-C7) arildir, burada Ra ve Rb'nin her biri is isteğe bağlı olarak --(C1-C4) alkoksi ile sübstitüe edilir; R1, R2, ve R3, bağımsız olarak hidrojen, halojen, siyano veya --(C6-C10) arildir, burada söz konusu --(C6-C10) aril isteğe bağlı olarak halojen ile sübstitüe edilir, bunun koşulu R1, R2, ve R3'ten en fazla bir tanesinin hidrojen olması ve R4 ve R5'in hidrojen olmasıdır.
TR2019/00515T 2010-01-14 2011-01-13 Bir adrenal hormonunu modifiye eden ajanın kullanımı. TR201900515T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
TR201900515T4 true TR201900515T4 (tr) 2019-02-21

Family

ID=43735742

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00515T TR201900515T4 (tr) 2010-01-14 2011-01-13 Bir adrenal hormonunu modifiye eden ajanın kullanımı.

Country Status (33)

Country Link
US (2) US8609862B2 (tr)
EP (2) EP2523731B1 (tr)
JP (4) JP5602250B2 (tr)
KR (1) KR101412206B1 (tr)
CN (2) CN105440038A (tr)
AU (1) AU2011205290C1 (tr)
BR (1) BR112012017458B1 (tr)
CA (1) CA2786443C (tr)
CL (1) CL2012001961A1 (tr)
CY (2) CY1121320T1 (tr)
DK (1) DK2523731T3 (tr)
ES (1) ES2707596T3 (tr)
HR (1) HRP20190064T1 (tr)
HU (2) HUE041967T2 (tr)
IL (1) IL220804A0 (tr)
LT (2) LT2523731T (tr)
LU (1) LUC00159I2 (tr)
MA (1) MA33904B1 (tr)
ME (1) ME03371B (tr)
MX (2) MX354022B (tr)
NL (1) NL301043I2 (tr)
NO (1) NO2020012I1 (tr)
NZ (1) NZ601077A (tr)
PL (1) PL2523731T3 (tr)
PT (1) PT2523731T (tr)
RS (1) RS58234B1 (tr)
RU (1) RU2598708C2 (tr)
SG (1) SG182393A1 (tr)
SI (1) SI2523731T1 (tr)
TN (1) TN2012000352A1 (tr)
TR (1) TR201900515T4 (tr)
WO (1) WO2011088188A1 (tr)
ZA (1) ZA201205058B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602250B2 (ja) * 2010-01-14 2014-10-08 ノバルティス アーゲー 副腎ホルモン修飾剤の使用
CN103037864A (zh) 2010-06-16 2013-04-10 安比拉神经疗法公司 用于治疗成瘾、精神障碍和神经变性疾病的组合物和方法
AR086665A1 (es) 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
CA2863339C (en) * 2012-01-17 2021-03-23 Novartis Ag Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
EP2836228B1 (en) * 2012-04-12 2024-03-20 Novartis AG Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
MX2016017315A (es) * 2014-07-07 2017-04-27 Novartis Ag Formas de dosificacion farmaceutica.
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
AU2016210899B2 (en) * 2015-01-29 2019-03-07 Recordati Ag Process for the production of condensed imidazolo Derivatives
WO2016164476A2 (en) 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
CA2990413A1 (en) * 2015-06-22 2016-12-29 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
CA3055940A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DK1121111T3 (da) 1998-10-15 2010-05-31 Imp Innovations Ltd Forbindelser til behandling af vægttab
WO2002066468A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
CA2645678A1 (en) 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
BRPI0712557A2 (pt) * 2006-05-26 2013-07-02 Novartis Ag inibidores de aldosterona sintase e/ou 11 beta-hidrolase
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2660701A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
AU2007333902A1 (en) * 2006-12-18 2008-06-26 Novartis Ag 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5602250B2 (ja) * 2010-01-14 2014-10-08 ノバルティス アーゲー 副腎ホルモン修飾剤の使用
CA2863339C (en) * 2012-01-17 2021-03-23 Novartis Ag Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
EP2836228B1 (en) * 2012-04-12 2024-03-20 Novartis AG Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Also Published As

Publication number Publication date
PL2523731T3 (pl) 2019-04-30
IL220804A0 (en) 2012-08-30
HUE041967T2 (hu) 2019-06-28
US8609862B2 (en) 2013-12-17
JP2018150326A (ja) 2018-09-27
CN102711916A (zh) 2012-10-03
LT2523731T (lt) 2019-02-11
CA2786443C (en) 2018-12-11
EP2523731B1 (en) 2018-10-24
RS58234B1 (sr) 2019-03-29
BR112012017458A2 (pt) 2017-12-19
RU2012134510A (ru) 2014-02-20
AU2011205290A1 (en) 2012-08-02
DK2523731T3 (en) 2019-02-04
JP2015013859A (ja) 2015-01-22
TN2012000352A1 (en) 2014-01-30
JP6425688B2 (ja) 2018-11-21
JP2013517280A (ja) 2013-05-16
JP6181610B2 (ja) 2017-08-16
LUC00159I1 (tr) 2020-06-16
SI2523731T1 (sl) 2019-02-28
MA33904B1 (fr) 2013-01-02
NL301043I1 (nl) 2020-06-17
US20140171392A1 (en) 2014-06-19
US20120295888A1 (en) 2012-11-22
ME03371B (me) 2020-01-20
CN102711916B (zh) 2015-09-02
MX2012008212A (es) 2012-08-03
SG182393A1 (en) 2012-08-30
US9434754B2 (en) 2016-09-06
KR20120116482A (ko) 2012-10-22
KR101412206B1 (ko) 2014-06-25
EP2523731A1 (en) 2012-11-21
JP2017002063A (ja) 2017-01-05
CN105440038A (zh) 2016-03-30
CY1121320T1 (el) 2020-05-29
EP3527208A1 (en) 2019-08-21
ZA201205058B (en) 2014-04-30
WO2011088188A1 (en) 2011-07-21
PT2523731T (pt) 2019-01-21
NL301043I2 (nl) 2020-07-06
MX354022B (es) 2018-02-08
JP5602250B2 (ja) 2014-10-08
AU2011205290B2 (en) 2014-06-26
HUS2000018I1 (hu) 2020-07-28
RU2598708C2 (ru) 2016-09-27
CY2020018I1 (el) 2020-11-25
CY2020018I2 (el) 2020-11-25
HRP20190064T1 (hr) 2019-03-08
HUS000508I2 (hu) 2021-03-29
CA2786443A1 (en) 2011-07-21
LTC2523731I2 (lt) 2022-05-10
LUC00159I2 (tr) 2021-07-06
BR112012017458B1 (pt) 2020-10-20
NO2020012I1 (no) 2020-06-09
NZ601077A (en) 2014-07-25
ES2707596T3 (es) 2019-04-04
AU2011205290C1 (en) 2014-11-06
CL2012001961A1 (es) 2013-03-22
LTPA2020512I1 (lt) 2020-07-27

Similar Documents

Publication Publication Date Title
TR201900515T4 (tr) Bir adrenal hormonunu modifiye eden ajanın kullanımı.
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
JP2012144574A5 (tr)
EA201500300A1 (ru) Способы применения с-мет-модуляторов
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA200700642A1 (ru) Способы лечения эпилептогенеза и эпилепсии
EA201291414A1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
EA201590693A1 (ru) Ингибиторы gdf-8
EA200800422A1 (ru) Способы лечения заболеваний, обусловленных химическими веществами
EA201290919A1 (ru) Индазольные соединения и их применение
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA200901241A1 (ru) Соединения для лечения гепатита с
JP2013507434A5 (tr)
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
EA200800294A1 (ru) Способы нейропротекции
EA201391334A1 (ru) Ингибиторы hsp90
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
MX2022004808A (es) Métodos para tratar el cáncer de próstata.
TW200744575A (en) Methods of treating epileptogenesis
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
JP2018502100A5 (tr)
MX345264B (es) Derivado de azol.
EA201070819A1 (ru) Соединения n-фенилимидазо[1,2-a]пиридин-2-карбоксамида, их получение и их применени в терапии
WO2014176510A3 (en) N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and their use in treating cancer
TH154720A (th) การใช้สารให้การดัดแปร-อะดรีนัล ฮอร์โมน